Full history for every metric is available with a Kvantra account
Hybrigenics S.A. (ALHYG.PA)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | €m | -1 | -1 | |||||
| Net profit | €m | -8 | -1 | -0 | 0 | -1 | -19 | -19 |
| EPS reported | € | -0.05 | -0.05 | |||||
| Operating cashflow per share | € | 0.00 | 0.00 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | 0.00 | 0.00 | |||||
| Free cash flow | €m | - | 0 | |||||
| Net debt | €m | 3 | 3 | |||||
| Book value equity | €m | -5 | -5 | |||||
| Book value per share | € | -0.01 | -0.01 | |||||
| Number of shares | m | 383.15 | 383.15 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.82 | -0.84 | |||||
| P/S LTM | x | 22.16 | 10.28 | |||||
| P/FCF LTM | x | 0.00 | 0.00 | |||||
| EV/EBITDA LTM | x | -26.06 | -15.94 | |||||
| EV/Sales LTM | x | 30.60 | 18.72 | |||||
| Earnings Yield LTM | % | -221.57% | -477.56% | |||||
| FCF Yield | % | 0.00% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | 402.20% | -679.52% | |||||
| ROIC | % | -66.18% | -66.18% | |||||
| Operating margin | % | -196.24% | -196.24% | |||||
| Gross margin | % | -38.14% | -38.14% | |||||
| FCF/Sales | % | 0.00% | 0.00% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | 0.00 | |||||
| Net Debt/EBITDA | x | -7.18 | -7.18 | |||||
| EBIT/Net interest | x | -5.66 | -5.66 | |||||
| Net debt/market cap | % | 38.06% | 82.02% | |||||
| Net debt/Equity | x | -0.69 | -0.69 | |||||
| Gross debt/equity | x | -0.69 | -0.69 | |||||
Company overview
Hybrigenics SA is a biotechnology firm, along with its subsidiaries, headquartered in Gallargues-le-Montueux, France. The company specializes in pioneering biotechnological advancements, particularly within oncology, regenerative medicine, and anti-aging therapies. Additionally, Hybrigenics is actively involved in developing technical solutions that leverage adipose tissue cells and stem cells. It operates as a subsidiary of Diagnostic Medical Systems S.A.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hybrigenics S.A. (ALHYG.PA)
Hybrigenics SA is a biotechnology firm, along with its subsidiaries, headquartered in Gallargues-le-Montueux, France. The company specializes in pioneering biotechnological advancements, particularly within oncology, regenerative medicine, and anti-aging therapies. Additionally, Hybrigenics is actively involved in developing technical solutions that leverage adipose tissue cells and stem cells. It operates as a subsidiary of Diagnostic Medical Systems S.A.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free